The efficacy of fosaprepitant to the moderate emetic risk intravenous chemotherapy
Phase 2
Recruiting
- Conditions
- Patients who are not effective by two antiemetic drugs(5-HT3 antagonist and dexamethasone) for the moderate emetic risk intravenous chemotherapy(L-OHP, CPT-11, CBDCA)
- Registration Number
- JPRN-UMIN000009311
- Lead Sponsor
- Division of Clinical Oncology, Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Serious complications (e.g. severe liver disfunction or renal disfunction) 2)Patients with factors besides chemotherapy(e.g. brain tumor, passage disorder of digestive tract, active digestive ulcer, brain metastases) 3)Poorly controlled diabetes 4)Pregnant or lactating women or women of childbearing potential 5)Patients during pimozide administration 6)Inadequate physical condition, as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method >Patients rate who required triple-drug therapy because of a digestive symptom(nausea and vomiting) >Improvement rate of the digestive symptom(nausea and vomiting) by the triple-drug therapy
- Secondary Outcome Measures
Name Time Method >Patients rate without vomiting >Patients rate of Complete Response (without vomiting and rescue) >Patients rate of Complete Protection (without vomiting, rescue, moderate or severe nausea) >Patients rate without nausea >Patients rate without moderate or severe nausea >Frequency distribution of nausea and vomiting >Successful treatment period >Intake situation